Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940380 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A | |
| SCHEMBL17659123 | 0.81 | DRD2 (0.51) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL19262490 | 0.81 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL13993849 | 0.80 | HTR1A (0.50) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL7366715 | 0.79 | KDM4E (0.51) | ALDH1A1POLBKDM4EMAPTDRD2 | |
| SCHEMBL16803397 | 0.79 | KDM4E (0.67) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL9300032 | 0.79 | MAPT (0.60) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL24309781 | 0.76 | MAPT (0.62) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL29566344 | 0.76 | MAPT (0.62) | ALDH1A1L3MBTL1POLBKDM4EMAPT | |
| SCHEMBL24446023 | 0.76 | MAPT (0.48) | ALDH1A1L3MBTL1KDM4EMAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-101415691-B | Triazole derivatives | TAISHO PHARMACEUTICAL CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| CN-101415691-A | Triazole derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-1988083-A1 | TRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3992/4885L3MBTL1 4300/4885POLB 3593/4885 |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | ALDH1A1 2519/4885L3MBTL1 2797/4885POLB 4784/4885 |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | ALDH1A1 2599/4885L3MBTL1 2859/4885POLB 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.